IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	LIECHTI; Matthias Emanuel	Confirmation No.: 8795
Serial No.:	17/238,088	Group No.:
Filing or 371(c) Date:	April 22, 2021	Examiner:
Entitled: MDMA TREA	ATMENT TO ENHANCE ACUTE	EMOTIONAL EFFECTS PROFILE OF LSD,

PSILOCYBIN, OR OTHER PSYCHEDELICS

THIRD-PARTY PRE-ISSUANCE SUBMISSION

Examiner:

The following documents, which are also identified in the Form PTO/SB/429 filed herewith, are submitted for your consideration as being of potential relevance to the examination of the present application:

- SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8.
- Int'l Pat. App. Pub. No. WO/2021/202730 "MOLECULARLY-INITIATED, EXPERIENTIALLY-DELIVERED TREATMENTS AND SYSTEMS FOR PRACTICING SAME" (Published October 7, 2021)
- LICHT (2012) "Simultaneous polysubstance use among Danish 3,4methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases" Hum. Psychopharmacol. Clin. Exp. 27: 352–363.
- SCHECHTER (1998) "Candyflipping': Synergistic discriminative effect of LSD and MDMA" European Journal of Pharmacology. 341(2-3)131-134.
- LIECHTI (2001) "Gender differences in the subjective effects of MDMA" Psychopharmacology. 154, 161–168.
- 6. WHITE (1996) "THE EFFECTS OF METHYLENEDIOXYMETHAMPHETAMINE (MDMA, "ECSTASY") ON MONOAMINERGIC NEUROTRANSMISSION IN THE CENTRAL NERVOUS SYSTEM" Progress in Neurobiology. 49, 455-479.

- SANTOS-LONGHURST (2020) "LSD and MDMA: What to Know About Candyflipping" Healthline. Retrieved February 11 2020. https://web.archive.org/web/20200211232126/https://www.healthline.com/health/lsd-and-mdma
- 8. BOYS (2001) "Understanding reasons for drug use amongst young people a functional perspective" Health Education Research. 16(4):457-469.
- HOLZE (2019) "Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects" Neuropsychopharmacology. 45:462–471.
- OLSON (2020) "Tripping on nothing: placebo psychedelics and contextual factors" Psychopharmacology. 237:1371–1382.
- **11.** SMIGIELSKI (2019) "Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat" Scientific Reports. 9:1-13.
- Int'l Pat. App. No. WO/2020/157569 "METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVIORAL, AND/OR MOOD DISORDERS" (Published August 6th, 2020)
- VAN WELL (2012) "Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors" PLoS One. 7(7)1-8.
- HALBERSTADT (2018) Behavioral Neurobiology of Psychedelic Drugs. Springer ISBN: 978-3-662-55878-2
- Int'l Pat. App. Pub. No. WO/2016/199135 "AN IMPROVED CAPSULE FOR DELIVERING FLOWABLE SUBSTANCE" (Published December 15th, 2016)
- CHARY (2018) "Candyflipping and Other Combinations: Identifying Drug–Drug Combinations from an Online Forum" Frontiers Psychiatry. 9:1-9.
- DMT-NEXUS (2013) "Known substance-interactions and their effects" DMT-Nexus. Retrieved January 25, 2013. <u>https://web.archive.org/web/20130125065447/https://wiki.dmt-</u> nexus.me/Known substance-interactions and their effects
- B-E-H, INC. (2012) "Searching for Samadhi in West Philadelphia LSD, MDMA (Ecstacy) & Alcohol" Erowid. Retrieved January 20, 2012 <u>https://web.archive.org/web/20120120044616/https://erowid.org/experiences/exp.php?ID=79281</u>
- Kryptonite (2009) "A Glorious New Year LSD & MDMA (Ecstasy)" Erowid. Retrieved July 4th, 2010.

https://web.archive.org/web/20100704210848/https://www.erowid.org/experiences/exp.php?ID= 58609

20. DANFORTH (2016) "MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults" Progress in Neuro-Psychopharmacology and Biological Psychiatry. 64:237-249.

 LIECHTI (2017) "Alterations of consciousness and mystical-type experiences after acute LSD in humans" Psychopharmacology. 234:1499–1510.

Attached hereto is a claim chart providing a concise description of the relevance of each reference in the document list to the elements of the presently pending claims.

U.S.S.N. 17/238,088 Pending Claims	References
1. A method of enhancing positive therapeutic effects of a psychedelic, including	1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8.
the steps of: inducing a positive psychological state in an individual with an empathogen/entactogen	From page 3 "Most psycholytic sessions began with MDMA , then LSD or 2-CB were added mid-way. Sometimes sessions began with 2-CB or with LSD or on rare occasions other substances such as ayahuasca or psilocybin were used."
; administering a psychedelic to the individual; and enhancing a positive response to the	3. LICHT (2012) "Simultaneous polysubstance use among Danish 3,4- methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases" Hum. Psychopharmacol. Clin. Exp. 27: 352–363.
psychedelic.	From page 355 "The most prevalent observations were cannabis enhancing the effects of hallucinogens $(n = 17)$ and MDMA $(n = 7)$, MDMA and hallucinogens enhancing each other $(n = 11)$, hallucinogens enhancing each other $(n = 6)$, amphetamines $(n = 8)$ and cocaine $(n = 6)$ counteracting hallucinogens, and cocaine counteracting the effects of MDMA $(n = 7)$."
2. The method of claim 1, wherein the empathogen/entactogen are administered in the	1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8.
same dosage form or in separate dosage forms as the psychedelic.	From page 3 "Most psycholytic sessions began with MDMA, then LSD or 2-CB were added mid-way. Sometimes sessions began with 2-CB or with LSD or on rare occasions other substances such as ayahuasca or psilocybin were used."
	4. SCHECHTER (1998) "Candyflipping': Synergistic discriminative effect of LSD and MDMA" European Journal of Pharmacology. 341(2-3)131-134.
	From page 132 "Interspersed between test/training maintenance with 1.5 mg/kg MDMA or saline sessions were test sessions in which the animal received either a low dose of MDMA (0.15 mg/kg) or a low dose of LSD (0.04 mg/kg) or both drugs administered at the same time ."
3. The method of claim	12. Int'l Pat. App. No. WO/2020/157569 "METHODS AND
2, wherein the	COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL COGNITIVE
and psychedelic are in	BEHAVIORAL, AND/OR MOOD DISORDERS" (Published August 6th,
the same dosage form	2020)
and have different	From claim 1 "A method of managing a neurological condition or one or
release profiles.	more symptoms thereof in a subject in need thereof, comprising

	 administering to the subject a pharmaceutical composition comprising: a) a therapeutically effective amount of one or more 5HT receptor agonist or a pharmaceutically acceptable salt, solvate, metabolite, derivative, or prodrug thereof." From claim 8 "The method of any one of the preceding claims, wherein the pharmaceutical composition comprises a controlled release component and an immediate release component." 13. VAN WELL (2012) "Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors" PLoS One. 7(7):1-8. From page 1 "3,4-Methylenedioxymethamphetamine (MDMA) is a serotonin (5-HT) agonist and a reuptake inhibitor of serotonin and dopamine (DA) that has been shown to affect mood [1] and impulsivity during intoxication [2], [3], [4] and abstinence [5], [6]. Mood has been shown to be affected by fluctuations in 5-HT levels."
	14. HALBERSTADT (2018) Behavioral Neurobiology of Psychedelic Drugs. Springer ISBN: 978-3-662-55878-2
	From page 50 "Although hallucinogens do not bind exclusively to 5-HT2A receptors (LSD binds to most 5-HT receptor sub-types as well as to dopaminergic and adrenergic receptors), it has been evidenced in both humans and experimental animals that the activation of 5-HT2A receptors is necessary to generate hallucinogenesis and a related behavioral response in animals."
4. The method of claim 1, wherein the empathogen/entactogen is chosen from the	1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8.
group consisting of 3,4- methylenedioxymetha mphetamine (MDMA), 3,4- methylendioxyampheta	From page 3 "Most psycholytic sessions began with MDMA , then LSD or 2-CB were added mid-way . Sometimes sessions began with 2-CB or with LSD or on rare occasions other substances such as ayahuasca or psilocybin were used."
mine (MDA), 3,4,- methylenedioxyethyla mphetamine (MDEA), 5.6-methylenedioxy-2-	16. CHARY (2018) "Candyflipping and Other Combinations: Identifying Drug–Drug Combinations from an Online Forum" Frontiers Psychiatry. 9:1-9.
aminoindane (MDAI), mephedrone, methylone, 3-MMC, homologues thereof,	From page 5 "In the synthetic hallucinogen, LSD is a hub that bridges two subislands. The left subisland of the hallucinogen island contains substances canonically thought to be anticholinergic. Hyoscine and hyoscyamine are tropane alkaloids found in jimson weed. The right subisland contains amphetamine derivatives, such as MDMA and the MDMA derivatives

analogues thereof, and prodrugs thereof.	(bath salts), bk-MDMA (β-keto MDMA; methylone) and bk-MDEA (ethylone)."
	17. DMT-NEXUS (2013) "Known substance-interactions and their effects" DMT-Nexus. Retrieved January 25, 2013. https://web.archive.org/web/20130125065447/https://wiki.dmt- nexus.me/Known_substance-interactions_and_their_effects
5. The method of claim 4, wherein the empathogen/entactogen is MDMA and is	1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8.
administered in a dose of 20-200 mg.	 From page 3 "The choice and dosages of substances used for the sessions MDMA: 80–130 mg LSD: 50–200μg"
6. The method of claim 1, wherein the psychedelic is chosen from the group	1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8.
consisting of psilocybin, psilocin, lysergic acid diethylamide (LSD), mescaline	From page 3 "Most psycholytic sessions began with MDMA , then LSD or 2-CB were added mid-way . Sometimes sessions began with 2-CB or with LSD or on rare occasions other substances such as ayahuasca or psilocybin were used."
dimethyltryptamine (DMT), 2,5-dimethoxy- 4-iodoamphetamine (DOI), 2,5-dimethoxy- 4-bromoamphetamie	17. DMT-NEXUS (2013) "Known substance-interactions and their effects" DMT-Nexus. Retrieved January 25, 2013. https://web.archive.org/web/20130125065447/https://wiki.dmt- nexus.me/Known_substance-interactions_and_their_effects
(DOB), phenethylamine or tryptamine psychedelics, salts thereof, analogs thereof, prodrugs	

thereof and	Intreaser secure https://wiki.dmt-nexus.meKnown_substance-interactions_and_their_effects
homologues thereof	20 20 20 20 20 20 20 20 20 20 20 20 20 2
noniologues mereor.	Mescaline + MDMA
	Mescaline + MDMA
	Combination: OK Generic information:
	User descriptions: Dante 📀 Nice combo, but it wasn't enough to understand its effects.
	Interese secure https://whi.dml-nexus.moKnown_substance-interactions_and_their_offects
	Mushrooms + MDMA
	Combinetion: OK
	Generic Information:
	User descriptions: House 😑 OK. Protound synergy. Great for meditation and dance
	Instruction Section 25 Go DCC 200 MAY O 0 0
	MDAI + DMT MDAI + DMT ()
	Combination: OK
	Generic Information: Vaporized hits of DMT seem harder to break through on, but the effect of the DMT seem protonged. Strange vauals (small
	User descriptions: Orion Pippoint kalelobaccope patters appear and dissappear), last for longer than the spice effects would last. by the 25 minutes longer. Does not seem dangerous, but the fact it makes open eye visuals linger for so long is interesting
	Nine-Juki dai awa malfanan substanon jalametinan and their allende
	LSD + MDAI
	LSD + MDAI
	Combination: OK Genetic information:
	User descriptions: The Traveler 📀 The MDAI gives a suphoric effect to the LSD experience.
7 The method of claim	1 SESSA (2015) "Underground MDMA ISD and 2 CB assisted
6 wherein the	individual and group psychotherapy in Zurich: Outcomes, implications and
0, wherein the	commentary" Drug Science, Policy and Law 2(0):1.8
is administered in a	commentary Drug Science, Foncy and Law. 2(0).1-8.
dogo of 0.05.0.2 mg	From name 2 "The choice and decompose of substances used for the sessions
uose of 0.05-0.5 mg.	From page 5 The choice and dosages of substances used for the sessions
	• MDMA: 80–130 mg
	• LSD: 50–200µg [*]
8. The method of claim	1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted
1, wherein the	individual and group psychotherapy in Zurich: Outcomes, implications and
empathogen/entactogen	commentary" Drug Science, Policy and Law. 2(0):1-8.
is administered at a	
time chosen from the	From page 3 "Most psycholytic sessions began with MDMA, then LSD or
group consisting of	2-CB were added mid-way. Sometimes sessions began with 2-CB or with
before administering	LSD or on rare occasions other substances such as ayahuasca or psilocybin
the psychedelic, at the	were used."
same time as	
administering the	4. SCHECHTER (1998) "Candyflipping': Synergistic discriminative effect
psychedelic, after	of LSD and MDMA" European Journal of Pharmacology. 341(2-3)131-134.
administering the	
psychedelic, and before	From page 132 "Interspersed between test/training maintenance with 1.5
and after administering	mg/kg MDMA or saline sessions were test sessions in which the animal
the psychedelic.	

	received either a low dose of MDMA (0.15 mg/kg) or a low dose of LSD (0.04 mg/kg) or both drugs administered at the same time ."
	18. B-E-H, INC. (2012) "Searching for Samadhi in West Philadelphia LSD, MDMA (Ecstacy) & Alcohol" Erowid. Retrieved January 20, 2012. https://web.archive.org/web/20120120044616/https://erowid.org/experience s/exp.php?ID=79281
	"Each person is to take 2 hits of LSD followed by 1 pill of MDMA approximately 3.5 hrs thereafter ."
	19. Kryptonite (2009) "A Glorious New Year LSD & MDMA (Ecstasy)" Erowid. Retrieved July 4th, 2010. <u>https://web.archive.org/web/20100704210848/https://www.erowid.org/experiences/exp.php?ID=58609</u>
	A Glorious New Year LSD & MIDMA (Ecstasy) by Systematic
	DOSE: T+ 0.00 1 tablet oral MDMA (pill / tablet) T + 2:00 2 drops oral LSO (liquid) T + 2:00 1 tablet oral MDMA (pill / tablet) T + 4:00 1 tablet oral MDMA (pill / tablet) T + 4:00 1 tablet oral MDMA (pill / tablet) T + 4:00 1 tablet oral MDMA (pill / tablet) T + 7:30 4 drops oral LSO (liquid) T + 7:30 4 drops oral MDMA (pill / tablet) T + 7:30 1 tablet oral MDMA (pill / tablet) T + 7:30 4 drops oral MDMA (pill / tablet) BODY WEIGHT: 70 kg I took a bottle of liquid acid to a friend*a new year's eve party. I usually take MDMA with halucinogens as it can help to reduce anxiety if things go pear-shaped. I was very fortamate in that I had managed to procure eight very cleant pills and look fine of these at roughtly two-hour intervals starting two hours before the first dose of acid.
9. The method of claim 1, wherein the psychedelic is a short- acting psychedelic, and the empathogen/entactogen is administered 1-2 hours before the short-	1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8.
	From page 3 "Most psycholytic sessions began with MDMA , then LSD or 2-CB were added mid-way . Sometimes sessions began with 2-CB or with LSD or on rare occasions other substances such as ayahuasca or psilocybin were used."
acting psychedenc.	19. Kryptonite (2009) "A Glorious New Year LSD & MDMA (Ecstasy)" Erowid. Retrieved July 4th, 2010. <u>https://web.archive.org/web/20100704210848/https://www.erowid.org/experiences/exp.php?ID=58609</u>
	"I took a bottle of liquid acid to a friend's new year's eve party. I usually take MDMA with hallucinogens as it can help to reduce anxiety if things go pear-shaped. I was very fortunate in that I had managed to procure eight very clean* pills and took five of these at roughly two-hour intervals starting two hours before the first dose of acid ."

10. The method of	2. Int'l Pat. App. Pub. No. WO/2021/202730 "MOLECULARLY-	
claim 1, wherein the	INITIATED, EXPERIENTIALLY-DELIVERED TREATMENTS AND	
individual has a	SYSTEMS FOR PRACTICING SAME" (Published October 7, 2021)	
psychiatric disorder		
chosen from the group	From claim 3 "The method of claim 2, wherein the psychedelic agent is	
consisting of	selected from the group consisting of: psilocybin, 3,4 -	
depression, anxiety,	Methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide	
anxiety related to life-	(LSD), N,N-Dimethyltryptamine (DMT), mescaline, peyote, 2,5-	
threatening disease,	dimethoxy-4-bromophenethylamine (2C-B), 2,5-Dimethoxy-4-	
obsessive-compulsive	methylamphetamine (DOM), NBOMes (N-methoxybenzyl), and any	
disorder, personality	combination thereof."	
disorder, and addiction.		
	From claim 14 "The method according to any one of claims 1 to 13, wherein the individual is suffering from a mental health condition selected from the group consisting of: depression , anxiety , post-traumatic stress disorder (PTSD), addiction , and any combination thereof."	
	12. Int'l Pat. App. No. WO/2020/157569 "METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVIORAL, AND/OR MOOD DISORDERS" (Published August 6th, 2020)	
	2020)	
	From claim 1 "A method of managing a neurological condition or one or more symptoms thereof in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising: a) a therapeutically effective amount of one or more 5HT receptor agonist or a pharmaceutically acceptable salt, solvate, metabolite, derivative, or prodrug thereof."	
	From claim 43 "The method of any one of claims 1-38, wherein the neurological condition is depression , bipolar disorder, anxiety, social anxiety , post-traumatic stress disorder (PTSD), panic disorder, phobia, schizophrenia, psychopathy, or antisocial personality disorder ."	
	From claim 47 "The method of claim 46, wherein the compulsive disorder is obsessive compulsive disorder (OCD) , gambling, or aberrant sexual behavior."	
	13. VAN WELL (2012) "Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors" PLoS One. 7(7):1-8.	
	From page 1 "3,4-Methylenedioxymethamphetamine (MDMA) is a serotonin (5-HT) agonist and a reuptake inhibitor of serotonin and dopamine (DA) that has been shown to affect mood [1] and impulsivity	

	 during intoxication [2], [3], [4] and abstinence [5], [6]. Mood has been shown to be affected by fluctuations in 5-HT levels." 14. HALBERSTADT (2018) Behavioral Neurobiology of Psychedelic Drugs. Springer ISBN: 978-3-662-55878-2 From page 50 "Although hallucinogens do not bind exclusively to 5-HT2A receptors (LSD binds to most 5-HT receptor sub-types as well as to dopaminergic and adrenergic receptors), it has been evidenced in both humans and experimental animals that the activation of 5-HT2A receptors is necessary to generate hallucinogenesis and a related behavioral response in animals"
11. The method of claim 1, wherein said enhancing step further includes the step of reducing bad drug effects chosen from the group consisting of anxiety, fear, fear of loss of body control, anxious-ego dissolution, disembodiment, fear of impaired thought control, paranoia, panic, negative thoughts, grooming, nadir effects, and combinations thereof.	 SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8. From page 4 "But of the 97 clients who underwent psycholytic psychotherapy, the qualitative outcomes were overwhelmingly positive. There were no serious adverse reactions to the substances, no psychoses, no hospitalisations and no suicides of any clients who were actively undergoing psycholytic therapy. Almost all of the clients describe improvements in their relationships and well-being at home and work." Smigielski (2019) "Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat" Scientific Reports. 9:1-13. From page 2 "Although the content and intensity of psychedelic experiences depend most critically on dosage, the same dose can induce a pleasurable state of self-dissolution or, under certain circumstances, a more distressing response associated with thought disturbances, fear of losing control, anxiety, or panic." From page 3 "5D-ASC is designed to quantify positive and negative forms of self/ego-dissolution, including perceptual alterations." HALBERSTADT (2018) Behavioral Neurobiology of Psychedelic Drugs. Springer ISBN: 978-3-662-55878-2 From page 277

	Primary Dimensions of ASCs – etiology independent - etiology dependent				
	OBN AED VIR AA VR				
	Positive derealization Anxious derealization ·Visual elementary and Auditory Altered vigilance				
	*Positivery experienced *Inought disorder complex hallumations alterations: *sleepiness loss of ego-boundaries *Delusion *Synesthesia *acoasms *dreaminess *Altered sense of time *Fear of loss of control *Changed meaning of percepts +Hypersensitivity				
	Positive, heightened mood or mania-like experience -over body -over body -facilitated recollection -facilitated imagination (voices)				
	Second-order Dimensions				
	Experience of Unity Insightfulness Elementary imagery				
	Spiritual Experiences				
	Bliss Bliss				
	Disembodiment of percepts				
12. The method of	1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted				
claim 1, wherein said	individual and group psychotherapy in Zurich: Outcomes, implications and				
enhancing step further	commentary" Drug Science, Policy and Law. 2(0):1-8.				
includes the step of					
improving good drug	From page 4 " Spiritual insights provide an awareness of being part of a				
group consisting of	greater whole, something bigger than onesen. Chefts often state that underlying all experience is the concept of love: binding together all other				
drug linking oceanic	underlying all experience is the concept of love; binding together all other aspects of life. This is very powerful for clients who have up till now power				
boundlessness.	enjoyed any significant experience of love. Feeling love is a fundamental				
experience of unity.	characteristic of psychedelic substances and particularly MDMA. The				
spiritual experience,	substance gives the clients an opportunity to see themselves as loving and,				
blissful state,	crucially, lovable individuals, which offers immense healing potential for				
insightfulness,	clients with traumatic histories."				
connectedness,					
mystical experiences,	From page 4 "But of the 97 clients who underwent psycholytic				
mystical-type effects,	psychotherapy, the qualitative outcomes were overwhelmingly positive.				
positive mood,	There were no serious adverse reactions to the substances, no psychoses, no				
transcendence of	hospitalisations and no suicides of any clients who were actively undergoing				
time/space, ineffability,	psycholytic therapy. Almost all of the clients describe improvements in				
well-being, trust,	their relationships and well-being at home and work."				
ieelings of love, feeling	8 DOVS (2001) "Understanding reasons for drug use an erest areas				
open, peak experience,	o. DO I S (2001) Understanding reasons for drug use amongst young				
thereof	people a functional perspective meanin Education Research. 10(4):457-409.				
	From page 465				

	(n = 153)	Amphetamines $(n = 60)$	Ecstasy $(n = 43)$	(n = 17)	(n = 44)	Alcohol $(n = 123)$
Used with [substance] to improve	its effects					
cannabis	-	16	18	8	14	93
amphetamines	37	-	20	7	3	29
ecstasy	55	39	_	11	19	45
LSD	24	10	9	-	3	6
cocaine	42	4	5	1	-	45
alcohol	110	38	23	4	29	-
hallucinogenic mushrooms	2	0	0	1	0	1
	Cannabis	Amphetamines	Ecstasy	LSD	Cocaine	Alcoho
	(n = 223)	(n = 19)	(n = 15)	(n = 3)	(n = 23)	(n = 1)
Used to help ease after effects of I	substancel					
cannabis	-	5	2	0	4	18
amphetamines	- 83	_	6	1	1	47
ecetaev	114	- 7	0	3	10	50
LSD	20	0	-	5	0	13
	29	1	1	_	0	24
	70	1	1	0	-	54
mphetamine in heal	thy subjec	ets" Neurop	sychoph	armacolo	ogy. 45:40	62–4
amphetamine in heal From page 462 "MD l iking , high, and ego Amphetamine increa	thy subject DMA prodiction dissolutions sed rating	ets" Neurop uced greate on compare s of activity	sychoph r ratings d with d- v and cor	armacolo of good ampheta	drug effe mine. d-	62–47 ects, red w
Imphetamine in heal From page 462 "MD iking , high, and ego Amphetamine increa LSD." From page 462 "MD empathy , and prosoc	thy subject MA prod dissolutions sed rating MA acute ciality"	ets" Neurop uced greate on compare s of activity ely induces	sychopha r ratings d with d- and cor feelings	of good ampheta accentratic	drug effe mine. d- on compa	62–4 [°] ects, red w ⁄e,



 blissful state ("I experienced boundless pleasure"), changed meaning of percepts ("Some everyday things acquired special meaning"), complex imagery ("I saw whole scenes roll by with closed eyes or in complete darkness"), audio-visual synaesthesia ("The colours of things seemed to be altered by sounds or noises"), and elementary imagery ("I saw colours with closed eyes or in complete darkness")."
11. Smigielski (2019) "Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat" Scientific Reports. 9:1-13.
 From page 2 "Although the content and intensity of psychedelic experiences depend most critically on dosage, the same dose can induce a pleasurable state of self-dissolution or, under certain circumstances, a more distressing response associated with thought disturbances, fear of losing control, anxiety, or panic." From page 3 "5D-ASC is designed to quantify positive and negative forms of self/ego-dissolution, including perceptual alterations." 14. HALBERSTADT (2018) Behavioral Neurobiology of Psychedelic Drugs. Springer ISBN: 978-3-662-55878-2
Primary Dimensions of ASCs – etiology independent - etiology dependent
OBN AED VIR AAA VR AAA AAAA AAA A
Second-order Dimensions
Experience of Unity Insightfulness Spiritual Experiences Bliss Disembodiment Changed meaning of percepts

21. LIECHTI (2017) "Alterations of consciousness and mystical-type
experiences after acute LSD in humans" Psychopharmacology. 234:1499–
1510.
From page 1501 "The 5D-ASC dimension "Oceanic Boundlessness" (27
items) measures derealization and depersonalization associated with positive
emotional states, ranging from heightened mood to euphoric exaltation. The
corresponding lower-order scales include "experience of unity," "spiritual
experience," "blissful state," and "insightfulness." The dimension
"Anxious Ego Dissolution" (21 items) summarizes ego disintegration and
loss of self-control phenomena associated with anxiety. The corresponding
lower-order scales include "disembodiment," "impaired control of
cognition," and "anxiety." The dimension "Visionary Restructuralization"
(18 items) consists of the lower-order scales "complex imagery,"
"elementary imagery," "audio-visual synesthesia," and "changed meaning
of percepts." Two additional dimensions describe "Auditory Alterations"
(15 items) and "Reduction of Vigilance" (12 items). The scale is well-
validated and widely used to characterize the subjective effects of various
psychedelic drugs (Carhart-Harris et al. 2016b; Hasler et al. 2004; Hysek et
al. 2011: Schmid et al. 2015: Vollenweider et al. 2007: Vollenweider and
Kometer 2010) "
From page 1501 "We also derived the four scale scores of the newly
validated revised 30-item MEO: mystical , positive mood transcendence of
time and space, and ineffability (Barrett et al. 2015) "
and and space, and menubility (Burtett et al. 2010).
From nage 1504
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

	Table 1 Statistics for the effects							
	of LSD in the 5D-ASC and MEQ		LSD 10)0 μg	LSD 20	0 μg	LSD 10	0 vs. 200 μg
			I test v	s. placebo	I test vs	. placebo	1 test	
			T=	P=	T=	P=	T =	<i>P</i> =
		5 Dimensions Altered States of Con	sciousness	(ASC) scale				
		Total ASC score	9.72	< 0.001	10.02	< 0.001	2.23	< 0.05
		Oceanic boundlessness	8.44	< 0.001	9.61	< 0.001	1.89	NS
		Anxious ego dissolution	6.43	< 0.001	4.01	< 0.001	1.50	NS
		Visionary restructuralization	9.79	< 0.001	15.32	< 0.001	2.34	<0.05
		Auditory alterations	3.72	< 0.01	5.87	< 0.001	0.42	NS
		Reductions of vigilance	7.44	< 0.001	5.93	< 0.001	0.79	NS
		Experience of unity	6.85	< 0.001	7.77	< 0.001	0.68	NS
		Spiritual experience	4.31	< 0.001	3.91	< 0.001	1.10	NS
		Blissful state	6.56	< 0.001	8.27	< 0.001	3.00	< 0.01
		Insightfulness	4.11	< 0.001	5.81	< 0.001	2.28	<0.05
		Disembodiment	6.93	< 0.001	5.87	< 0.001	0.13	NS
		Impaired control and cognition	7.01	<0.001	5.04	<0.001	0.86	NS
		Anxiety	3.02	<0.001	2.04	NS	1.37	NS
		Complex imagery	7.10	<0.001	7.48	<0.001	0.51	NS
		Audio visual supethosia	9.90	<0.001	12.52	<0.001	1.96	IND
		Changed meaning of percents	6.25	<0.001	0.66	<0.001	2.20	<0.01
		Ego dissolution (item 71)	7.63	<0.001	5.32	<0.001	0.36	NS
		Mystical Effects Questionnaire (ME	(C43)	<0.001	5.52	<0.001	0.50	145
		Internal unity	NA.	NA	6.22	< 0.001	NA	NA
		External unity	NA	NA	6.08	< 0.001	NA	NA
		Sacredness	NA	NA	6.80	< 0.001	NA	NA
		Noetic quality	NA	NA	5.71	< 0.001	NA	NA
		Deeply felt positive mood	NA	NA	11.43	< 0.001	NA	NA
		Transcendence of time/space	NA	NA	10.63	< 0.001	NA	NA
		Ineffability	NA	NA	16.22	< 0.001	NA	NA
		Mystical Effects Questionnaire (ME	Q30)					
		Mystical	NA	NA	5.99	< 0.001	NA	NA
		Positive mood	NA	NA	13.13	< 0.001	NA	NA
		Transcendence of time/space	NA	NA	11.12	< 0.001	NA	NA
		Ineffability	NA	NA	25.14	< 0.001	NA	NA
		MEC30 total score	NA	NA	14.91	< 0.001	NA	NA
		Sixteen subjects participated in the hig Dependent T tests were performed to	gh-dose stu assess diff	ady (200 μg) at ferences from p	nd 24 subject	cts in the mod 1 independent	erate-dose s	tudy (100 μg). e performed to
		Sixteen subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 NA not assessed	gh-dose stu assess diff LSD	ady (200 μg) an ferences from p	nd 24 subjec placebo, and	cts in the mod 1 independent	erate-dose s T tests wer	tudy (100 μg). e performed to
13. The method of	5 LIECHTI (200	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 NA not assessed	gh-dose stu assess diff LSD	idy (200 µg) an ferences from p	nd 24 subject placebo, and	cts in the mod 1 independent ctive e	erate-dose s T tests wer	tudy (100 μg). e performed to
13. The method of	5. LIECHTI (200	Sixteen subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 NA not assessed 1) "Gender difference	gh-dose stu assess diff LSD	idy (200 µg) at ferences from p	nd 24 subject placebo, and subje	ts in the mod d independent ctive e	erate-dose s T tests wer	tudy (100 μg). e performed to S Of
13. The method of claim 1, wherein the	5. LIECHTI (200 MDMA" Psychoj	Sixteen subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 NA not assessed 1) "Gender difference pharmacology. 154	gh-dose stu assess diff LSD ences 4, 16	in the 1–168.	nd 24 subjector, and	ts in the mod d independent ctive e	erate-dose s T tests wer	tudy (100 µg). performed to
13. The method of claim 1, wherein the empathogen/entactogen	5. LIECHTI (200 MDMA" Psychop	Sixteen subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 <i>NA</i> not assessed 1) "Gender difference pharmacology. 154	gh-dose stu assess diff LSD ences 4, 16	in the $1-168$.	nd 24 subjec placebo, and subje	cts in the mod d independent ctive e	erate-dose s T tests wer	tudy (100 µg). performed to
13. The method of claim 1, wherein the empathogen/entactogen	5. LIECHTI (200 MDMA" Psychoj	Sixteen subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 <i>NA</i> not assessed 1) "Gender difference pharmacology. 154	gh-dose stu assess diff LSD ences 4, 16	in the 1–168.	nd 24 subjec placebo, and subje	ts in the mod d independent ctive e	erate-dose s T tests wer	tudy (100 µg). e performed to
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6	5. LIECHTI (200 MDMA" Psychop From page 163 "	Sixteen subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 <i>NA</i> not assessed 1) "Gender difference pharmacology. 154 F and P values for	ences 4, 16	in the 1–168.	nd 24 subject placebo, and subje main	cts in the model independent distribution of the set	erate-dose s and	tudy (100 µg). e performed to
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after	5. LIECHTI (200 MDMA" Psychop From page 163 "	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Fable 1. Subjective	ences 4, 16	in the $1-168$.	nd 24 subject placebo, and subje main	ets in the mod l independent ctive e effect:	erate-dose s	tudy (100 µg). e performed to
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 NA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective	ences 4, 16 signi	in the 1–168. ificant ects of	nd 24 subjee olacebo, and subje main MDN	ets in the mod l independent ctive e effect /IA be	erate-dose s T tests wer effects s and gan 3	tudy (100 µg). e performed to s of interactions 0–60 min
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 NA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea	ences 4, 16 signi ked a	in the 1–168. ificant ects of at 75–1	subje main MDN	ets in the mod l independent ctive e effect: IA be nin, an	erate-dose s T tests wer effects s and gan 3 ad las	tudy (100 µg). e performed to s of interactions 0–60 min ted for a
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad	Sixteen subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea	ences 4, 16 signi ked a	in the 1–168. ificant ects of at 75–1	subje subje main MDN	ets in the mod lindependent ctive e effect IA be hin, an	erate-dose s T tests wer effects s and gan 3 od las	tudy(100 μg). e performed to s of interactions 0–60 min ted for a
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration o	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h."	ences 4, 16 signi e effe ked :	in the 1–168. ificant ects of at 75–1	subje subje main MDN	ets in the mod independent ctive e effect: IA be hin, an	erate-dose s T tests wer effects s and gan 3 id las	tudy (100 μg). e performed to s of interactions 0–60 min ted for a
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration o	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of I <i>NA</i> not assessed (1) "Gender difference pharmacology. 154 F and P values for Fable 1. Subjective ministration, pea of 3.5h ."	ences 4, 16 signi e effe ked :	in the 1–168. ificant ects of at 75–1	subje main MDN	ets in the mod independent ctive e effect: AA be hin, an	erate-dose s T tests wer effects s and gan 3 id las	tudy (100 μg). e performed to s of interactions 0–60 min ted for a
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration o	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 <i>NA</i> not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h ."	ences 4, 16 signi ked :	in the 1–168. ificant ects of at 75–1	subje subje main MDN	ctive e effect IA be bin, an	ente-dose s T tests wer effects s and gan 3 id las	tudy (100 µg). e performed to s of interactions 0–60 min ted for a
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration o 7. SANTOS-LON	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Fable 1. Subjective ministration, pea of 3.5h ."	encess 4, 16 signified e effective ked a	in the 1–168. ificant ects of at 75–1 D and 1	nd 24 subjecto, and subjecto, and main MDN 20 m	ctive e effect (IA be iin, an	ente-dose s T tests wer effects s and gan 3 id las hat to	tudy (100 µg). e performed to s of interactions 0–60 min ted for a Know
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration o 7. SANTOS-LON About Candyfling	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 NA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h ." NGHURST (2020) ping" Healthline F	ences 4, 16 signi e effe ked :	in the 1–168. ificant ects of at 75–1	subje subje main MDN 20 m	ets in the mod lindependent ctive e effect: IA be hin, an IA: W	ente-dose s T tests wer effects s and gan 3 id las hat to	tudy (100 µg). e performed to s of interactions 0–60 min ted for a Know
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration of 7. SANTOS-LON About Candyflipp	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 NA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h." NGHURST (2020) ping" Healthline. F	ences t.SD ences 4, 16 signi e effe ked a "LSI ketrie	in the 1–168. ificant ects of at 75–1 D and 1 eved Fe	subje subje main MDN 20 m	ets in the mod l independent ctive e effect: IA be hin, an IA: W ry 11 2	ente-dose s T tests wer effects s and gan 3 ad las hat to 2020.	tudy (100 μg). e performed to s of interactions 0–60 min ted for a Know
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration of 7. SANTOS-LON About Candyflipp https://web.archiv	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h." NGHURST (2020) ping" Healthline. Five.org/web/202002	ences 4, 16 signi e effe ked : CLSI etrie	in the 1–168. ificant ects of at 75–1 D and 1 eved Fe 32126/1	subje subje main MDN 20 m	ctive e effect: IA be hin, an IA: W cy 11 2	ente-dose s T tests wer effects s and gan 3 ad las hat to 2020. 7.heal	tudy (100 µg). e performed to s of interactions 0–60 min ted for a Know thline.com/h
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration o 7. SANTOS-LON About Candyflipp https://web.archiv	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Fable 1. Subjective ministration, pea of 3.5h." NGHURST (2020) ping" Healthline. F	ences 4, 16 signi e effe ked a "LSI Retrie	in the 1–168. ificant ects of at 75–1 D and 1 eved Fe 32126/1	subje subje main MDN 20 m	ctive e effect: A be hin, an IA: W cy 11 2 //www	ente-dose s T tests wer effects s and gan 3 d las hat to 2020. 7.heal	tudy (100 µg). e performed to s of interactions 0–60 min ted for a Know thline.com/h
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration o 7. SANTOS-LON About Candyflipp https://web.archiv ealth/lsd-and-mdu	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h ." NGHURST (2020) ping" Healthline. F ve.org/web/202002 ma	ences 4, 16 signi e effe ked : CSD	in the 1–168. ificant ects of at 75–1 D and I eved Fe 32126/1	subje subje main MDN 20 m	ctive e effect: IA be in, an IA: W cy 11 2	ente-dose s T tests wer effects s and gan 3 d las hat to 2020. 7.heal	tudy (100 µg). e performed to s of interactions 0–60 min ted for a Know thline.com/h
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration o 7. SANTOS-LON About Candyflipp https://web.archiv ealth/lsd-and-mdn	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h ." NGHURST (2020) ping" Healthline. Five.org/web/202002 ma	encess 4, 16 signi e effe ked a "LSI Retrie	in the 1–168. ificant ects of at 75–1 D and 1 eved Fe 32126/1	nd 24 subjection and 24 subjec	ctive e effect (IA be hin, an IA: W cy 11 2 //www	ente-dose s T tests wer effects s and gan 3 d las hat to 2020. 7.heal	tudy (100 µg). e performed to s of interactions 0–60 min ted for a Know thline.com/h
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration o 7. SANTOS-LON About Candyflipp https://web.archiv ealth/lsd-and-mdr	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 NA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h ." NGHURST (2020) ping" Healthline. Five.org/web/202002 ma	ences 4, 16 signi e effe ked : CES Retrie	in the 1–168. ificant ects of at 75–1 D and 1 eved Fe 32126/1	nd 24 subjection and a	ctive e effect IA be inn, an IA: W cy 11 2 //www	ente-dose s 7 tests wer effects s and gan 3 id las hat to 2020. 7.heal	tudy (100 µg). a performed to s of interactions 0–60 min ted for a Know thline.com/h
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration of 7. SANTOS-LON About Candyflipp https://web.archiv ealth/lsd-and-mdr	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 NA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h ." NGHURST (2020) ping" Healthline. F ve.org/web/202002 ma is usually taken se	ences 4, 16 signi e effe ked : 21123	in the 1–168. ificant ects of at 75–1 D and 1 eved Fe 32126/1	subje subje main MDN 20 m	ctive e effect: IA be inn, an IA: W cy 11 2 //www LSD,	ente-dose s T tests wer effects s and gan 3 d las hat to 2020. 7.heal	tudy (100 µg). a performed to s of interactions 0–60 min ted for a Know thline.com/h ally kicks in
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration of 7. SANTOS-LON About Candyflipp https://web.archiv ealth/lsd-and-mdn "MDMA, which within 20 to 70 m	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h." NGHURST (2020) ping" Healthline. Five.org/web/202002 ma is usually taken see	ences 4, 16 signi e effe ked : CLSI etric	in the 1–168. ificant ects of at 75–1 D and 1 eved Fe 32126/1	after	ctive e effect: A be in, an IA: W cy 11 2 <u>//www</u> LSD,	ente-dose s T tests wer effects s and gan 3 d las hat to 2020. 7.heal typica	tudy (100 µg). e performed to s of interactions 0–60 min ted for a Know thline.com/h ally kicks in
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration of 7. SANTOS-LON About Candyflipp <u>https://web.archiv</u> ealth/lsd-and-mdr "MDMA, which within 20 to 70 m	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Fable 1. Subjective ministration, pea of 3.5h." NGHURST (2020) ping" Healthline. For ve.org/web/202002 ma is usually taken see ninutes and lasts from	ences 4, 16 signi e effe ked a "LSI etric 21123	in the 1–168. ificant ects of at 75–1 D and 1 eved Fe 32126/1	after ours.	ctive e effect: AA be hin, an IA: W y 11 2 <u>//www</u> LSD,	ente-dose s T tests wer effects s and gan 3 d las hat to 2020. 7.heal typica	tudy (100 µg). e performed to s of interactions 0–60 min ted for a Know thline.com/h ally kicks in
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration of 7. SANTOS-LON About Candyflipp <u>https://web.archiv</u> ealth/lsd-and-mdr "MDMA, which within 20 to 70 m	Sixten subjects participated in the hi Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Fable 1. Subjective ministration, pea of 3.5h." NGHURST (2020) ping" Healthline. F ve.org/web/202002 ma is usually taken see hinutes and lasts from	ences 4, 16 signi e effe ked a "LSI Retrie 21123	in the in the 1–168. ificant ects of at 75–1 D and 1 eved Fe 32126/1	after ours.	ctive e effect: IA be in, an IA: W cy 11 2 //www LSD,	ente-dose s T tests wer effects s and gan 3 d las hat to 2020. 7.heal typica	tudy (100 µg). e performed to s of interactions 0–60 min ted for a Know thline.com/h ally kicks in
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration of 7. SANTOS-LON About Candyflipp https://web.archiv ealth/lsd-and-mdn "MDMA, which within 20 to 70 m	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h ." NGHURST (2020) ping" Healthline. F ve.org/web/202002 ma is usually taken see ninutes and lasts free	encess 4, 16 signi e effe ked : "LSI Retrie 21123	in the in the 1–168. ificant ects of at 75–1 D and I eved Fe 32126/1	after after after after	ctive e effect: IA be in, an IA: W cy 11 2 //www LSD, "	ente-dose s T tests wer effects s and gan 3 d las hat to 2020. 7.heal typica	tudy (100 µg). a performed to a of interactions 0–60 min ted for a Know thline.com/h ally kicks in ment model
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration o 7. SANTOS-LON About Candyflipp https://web.archiv ealth/lsd-and-mdn "MDMA, which within 20 to 70 m 21. DANFORTH	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h ." NGHURST (2020) ping" Healthline. Five.org/web/202002 ma is usually taken see ninutes and lasts free (2016) "MDMA-a	encess 4, 16 signi e effe ked a "LSI etric 21123 everal om 3 assist	in the 1–168. ificant ects of at 75–1 D and I eved Fe 32126/1 hours to 6 he	after ours. apy:	ctive e effect (IA be independent (IA be in, an (IA: W cy 11 2 //www LSD, " A new	ente-dose s T tests wer effects s and gan 3 id las hat to 2020. 7.heal typica	tudy (100 µg). a performed to a of interactions 0–60 min ted for a Know thline.com/h ally kicks in ment model
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration of 7. SANTOS-LON About Candyflipp https://web.archiv ealth/lsd-and-mdr "MDMA, which within 20 to 70 m 21. DANFORTH for social anxiety	Sixten subjects participated in the hij Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed (1) "Gender difference pharmacology. 154 F and P values for Table 1. Subjective ministration, pea of 3.5h ." NGHURST (2020) ping" Healthline. Five.org/web/202002 ma is usually taken see ninutes and lasts fro (2016) "MDMA-a in autistic adults"	encess 4, 16 signi e effe ked a "LSI etric 21123 everal om 3 assist Prog	in the 1–168. ificant ects of at 75–1 D and 1 eved Fe 32126/1 l hours to 6 he ted then gress in	after ours. Sacebo, and subje main MDN bruan after ours. Sapy: Neun	ctive e effect (IA be inn, an IA: W cy 11 2 //www LSD, " A new co-Psy	ente-dose s 7 tests wer effects s and gan 3 id las hat to 2020. 7.heal typica v treat choph	tudy (100 µg). a performed to s of interactions 0–60 min ted for a Know thline.com/h ally kicks in ment model harmacology
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration of 7. SANTOS-LON About Candyflipp https://web.archiv ealth/lsd-and-mdh "MDMA, which within 20 to 70 m 21. DANFORTH for social anxiety and Biological Po	Sixten subjects participated in the hi Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed F and P values for Fable 1. Subjective ministration, pea of 3.5h ." NGHURST (2020) ping" Healthline. F ve.org/web/202002 ma is usually taken see ninutes and lasts free (2016) "MDMA-a in autistic adults"	ences 4, 16 signi e effe ked : "LSI etrie 21123 everal om 3 assist	in the in the 1–168. ificant ects of at 75–1 D and l eved Fe 32126/1 hours to 6 he ted then gress in	after ours. apy: Neun	ctive e effect: IA be in, an IA: W cy 11 2 //www LSD, " A new ro-Psy	ente-dose s T tests wer effects s and gan 3 d las hat to 2020. 7.heal typica	tudy (100 µg). a performed to a of interactions 0–60 min ted for a Know thline.com/h ally kicks in ment model harmacology
13. The method of claim 1, wherein the empathogen/entactogen reduces anxiety up to 6 hours after administration.	5. LIECHTI (200 MDMA" Psychop From page 163 " are presented in T after MDMA ad mean duration of 7. SANTOS-LON About Candyflipp https://web.archiv ealth/lsd-and-mdn "MDMA, which within 20 to 70 m 21. DANFORTH for social anxiety and Biological Ps	Sixten subjects participated in the hi Dependent 7 tests were performed to assess differences between doses of 1 MA not assessed T1) "Gender difference pharmacology. 154 F and P values for Fable 1. Subjective ministration, pea of 3.5h." NGHURST (2020) ping" Healthline. For ve.org/web/202002 ma is usually taken see ninutes and lasts fro (2016) "MDMA-a in autistic adults" sychiatry. 64:237-2	ences 4, 16 signi e effe ked a "LSI etric 21123 everal om 3 assist Prog 249.	in the in the 1–168. ificant ects of at 75–1 D and I eved Fe 32126/I I hours to 6 he ted then gress in	after ours. Trapy:	ctive e effect: AA be hin, an IA: W y 11 2 <u>//www</u> LSD, " A new ro-Psy	ente-dose s T tests wer effects s and gan 3 d las hat to 2020. 7.heal typica	tudy (100 µg). a performed to a of interactions 0–60 min ted for a Know thline.com/h ally kicks in ment model harmacology

	From page 237 " MDMA-assisted therapy could reduce social anxiety symptoms and increase social adaptability."
14. A composition comprising an empathogen/entactogen and a psychedelic in the same dosage form.	12. Int'l Pat. App. No. WO/2020/157569 "METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVIORAL, AND/OR MOOD DISORDERS" (Published August 6th, 2020)
	From claim 1 "A method of managing a neurological condition or one or more symptoms thereof in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising: a) a therapeutically effective amount of one or more 5HT receptor agonist or a pharmaceutically acceptable salt, solvate, metabolite, derivative, or prodrug thereof."
	From claim 8 "The method of any one of the preceding claims, wherein the pharmaceutical composition comprises a controlled release component and an immediate release component ."
	13. VAN WELL (2012) "Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors" PLoS One. 7(7):1-8.
	From page 1 "3,4-Methylenedioxymethamphetamine (MDMA) is a serotonin (5-HT) agonist and a reuptake inhibitor of serotonin and dopamine (DA) that has been shown to affect mood [1] and impulsivity during intoxication [2], [3], [4] and abstinence [5], [6]. Mood has been shown to be affected by fluctuations in 5-HT levels."
	14. HALBERSTADT (2018) Behavioral Neurobiology of Psychedelic Drugs. Springer ISBN: 978-3-662-55878-2
	From page 50 "Although hallucinogens do not bind exclusively to 5-HT2A receptors (LSD binds to most 5-HT receptor sub-types as well as to dopaminergic and adrenergic receptors), it has been evidenced in both humans and experimental animals that the activation of 5-HT2A receptors is necessary to generate hallucinogenesis and a related behavioral response in animals"
15. The composition of claim 14, wherein said empathogen/entactogen and said psychedelic have different release profiles.	12. Int'l Pat. App. No. WO/2020/157569 "METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVIORAL, AND/OR MOOD DISORDERS" (Published August 6th, 2020)

	From claim 1 "A method of managing a neurological condition or one or
	more symptoms thereof in a subject in need thereof, comprising
	administering to the subject a pharmaceutical composition comprising: a) a
	therapeutically effective amount of one or more 5HT receptor agonist or a
	pharmaceutically acceptable salt, solvate, metabolite, derivative, or prodrug
	thereof."
	From claim 8 "The method of any one of the preceding claims, wherein the pharmaceutical composition comprises a controlled release component and an immediate release component ."
	13. VAN WELL (2012) "Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors" PLoS One. 7(7):1-8.
	From page 1 "3,4-Methylenedioxymethamphetamine (MDMA) is a serotonin (5-HT) agonist and a reuptake inhibitor of serotonin and dopamine (DA) that has been shown to affect mood [1] and impulsivity during intoxication [2], [3], [4] and abstinence [5], [6]. Mood has been shown to be affected by fluctuations in 5-HT levels."
	14. HALBERSTADT (2018) Behavioral Neurobiology of Psychedelic Drugs. Springer ISBN: 978-3-662-55878-2
	From page 50 "Although hallucinogens do not bind exclusively to 5-HT2A receptors (LSD binds to most 5-HT receptor sub-types as well as to dopaminergic and adrenergic receptors), it has been evidenced in both humans and experimental animals that the activation of 5-HT2A receptors is necessary to generate hallucinogenesis and a related behavioral response in animals"
16. The composition of	12. Int'l Pat. App. No. WO/2020/157569 "METHODS AND
claim 14, wherein said	COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR
empathogen/entactogen	THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE,
is chosen from the	BEHAVIORAL, AND/OR MOOD DISORDERS" (Published August 6th,
group consisting of 3.4-	2020)
methylenedioxymetha	
mphetamine (MDMA).	From claim 1 "A method of managing a neurological condition or one or
3.4-	more symptoms thereof in a subject in need thereof. comprising
methylendioxvampheta	administering to the subject a pharmaceutical composition comprising: a) a
mine (MDA), 3.4	therapeutically effective amount of one or more 5HT receptor agonist or a
methylenedioxvethyla	pharmaceutically acceptable salt, solvate, metabolite, derivative, or prodrug
mphetamine (MDEA).	thereof."
5,6-methylenedioxy-2-	
aminoindane (MDAI).	From claim 8 "The method of any one of the preceding claims, wherein the
mephedrone,	pharmaceutical composition comprises a controlled release component
methylone, 3-MMC,	and an immediate release component."

homologues thereof.	
analogues thereof and	13 VAN WELL (2012) "Effects of Acute MDMA Intoxication on Mood
prodrugs thereof	and Impulsivity. Role of the 5-HT2 and 5-HT1 Receptors" PLoS One
F	7(7):1-8
	From nage 1 "3 4-Methylenedioxymethamphetamine (MDMA) is a
	serotonin (5-HT) agonist and a reuntake inhibitor of serotonin and
	donamine (DA) that has been shown to affect mood [1] and impulsivity
	during intoxication [2] [3] [4] and abstinence [5] [6] Mood has been
	shown to be affected by fluctuations in 5-HT levels "
	shown to be uncerted by indettations in 5 111 levels.
	14 HAI BERSTADT (2018) Behavioral Neuropiology of Psychedelic
	Drugs Springer ISBN: 078 3 662 55878 2
	Drugs. Springer 13DIN. 978-3-002-33878-2
	From page 50 "Although halluginggong do not hind avalugiyaly to 5 UT2A
	recenters (LSD binds to most 5 HT recenter sub types as well as to
	denomination and advantation receptor sub-types as well as to
	hyperine and experimental enimals that the activation of 5 LIT2 A recentors in
	numans and experimental animals that the activation of 5-H12A receptors is
	necessary to generate nanucinogenesis and a related behavioral response in
	anniais
	15 Int'l Dat Ann Dub No. WO/2016/100125 "AN IMPDOVED
	15. Int I Pat. App. Pub. No. WO/2010/199155 AN IMPROVED
	CAPSULE FOR DELIVERING FLOWABLE SUBSTANCE (Published
	December 15th, 2016)
	From claim 40 "The device of claim 40 wherein said at least one flowable
	rion claim 49 The device of claim 40, wherein said at least one nowable
	substance comprises a medicament selected from a group consisting of
	same, natural substances, medicaments for treatments for anergic minuts,
	incurcaments for treatments for osteoporosis, vaccinations and
	Immunizations, sexual dystunction drugs, medicaments for treatments for
	B12 deficiency, medicaments for smoking cessation, medicaments for
	treatment of gynecological problems, medicaments for treatment of other
	women's nealth issues, medicaments for general anesthetics, local
	anestnetics, opioid analgesics, agonist-antagonists and antagonists,
	antitussives, medicaments for treatment of motor disorders, antiepileptics,
	antipsychotics (neuroleptics), sedative-hypnotics, anxiolytics, and centrally
	acting muscle relaxants, medicaments for treatments for anxiety disorders,
	skeletal muscle relaxants, medicaments for treatments for Parkinson's
	disease, medicaments for treatments for Alzheimer's disease, medicaments
	for treatment of allergic minitis, steroids, corticosteroids, Flonase, Patanase,
	Beconase, antihistamines, Astelin, Otrivin, Livostin, Theramax, Avamys,
	Luteel, Sinofresh, Nasonex, Nasocort, Veramyst, medicaments for treatment
	of osteoporosis, Miacalcin, Fortical and Stadol, medicaments for
	vaccinations and immunizations, LAVIN, and influenza vaccines including
	FluMist, NasalFent. Calcitonin, parathyroid hormone, Neurotransmitters and
	neuromodulators, acetylcholine (ACH), Anticholinergic drugs, adenosine
	triphosphate (ATP), aspartate (Asp), beta-amyloid, beta-endorphin.

bradykinin, dopamine (DA), L-DOPA, Carbio-Dopa, epinephrine, dynorphins, endomorphins, enkephalins, 5-hydroxytryptamine (5-HT), Sumatriptan, Imitrex, Migranal, Zolmitriptan, Zomig, Gamma-aminobutyric acid (GABA), glutamate (glu), glycine, histamine, leptin, nerve growth factor and other growth factors), norepinephrine, nitric oxide, Substance P. alfentanil, desflurane, enflurane, etomidate, fentanyl, halothane, isoflurane, ketamine, methohexital, methoxyflurane, midazolam, morphine, nitrous oxide (N20), propofol, sevoflurane, Sufentanil, Sublimase, thiopental, benzocaine, bupivacaine, cocaine, lidocaine, prilocaine, procaine, ropivacaine, tetracaine, Opioid analgesics, agonist-antagonists, and antitussives, agonists, codeine, diphenoxylate, fentanyl, heroin and other opiods, cannabis and cannabinoids, hydrocodone, 1-alpha-acetyl-methadol, levomethadyl acetate, loperamide, meperidine, methadone, morphine, oxycodone, d-propoxyphene, combinations of opioids plus acetaminophen and asa, and tramadol, agonist/antagonists and antagonists, buprenorphine, butorphanol, nalbuphine, nalorphine, naloxone, naltrexone, nalmefene, pentazocine, codeine, dextromethorphan, and hydrocodone, medicaments for treatment of Parkinson's disease and motor disorders, amantadine, apomorphin, baclofen, benzodiazepines, benztropine, bromocriptine, carbidopa, cyclobenzaprine, dantrolene, dopamine, entacapone, haloperidol, L-DOPA, pergolide, pramiprexole, ropinerole, selegiline (deprenyl), trihexyphenidyl, rasagiline, azilect, selegiline, ladostigil, rotigotine, neupro, mono amine oxidase inhibitor, COMT inhibitor, antiepileptics, acetazolamide, carbamazepine, clonazepam, diazepam, ethosuximide, felbamate, gabapentin, Lamotrigine, lorazepam, phenobarbital, phenytoin, primidone, tiagabine, topiramate, valproic acid, Vigabatrin, Midazolam, antidepressants, amitriptyline, bupropion, citalopram, clomipramine, desipramine, fluoxetine, fluvoxamine, imipramine, nortriptyline, paroxetine, phenelzine, sertraline, trazodone, tranylcypromine, venlafaxine, antimanic drugs, carbamazepine, lithium carbonate valproic acid, antipsychotics (neuroleptics), chlorpromazine (CPZ), clozapine, fluphenazine, haloperidol, olanzapine, quetiapine, risperidone, sertindole, thioridazine, thiothixene, ziprasidone, sedative-hypnotics, anxiolytics, and centrally acting muscle relaxants, alprazolam, chloral hydrate, diphenhydramine, flumazenil, flurazepam, hydroxyzine, lorazepam, oxazepam, phenobarbital, temazepam, triazolam, zaleplon, Zolpidem, anxiety disorders and skeletal muscle relaxants, alprazolam, chlorazepate, chlordiazepoxide, diazepam, flumazenil (antagonist), lorazepam, oxazepam, amphetamine, caffeine, ephedrine, methamphetamine, methylphenidate, phentermine, sibutramine, disulfiram, ethanol, methanol, naltrexone, atropine, scopolamine, ketamine, lysergic acid diethylamide (LSD), MDMA (methylene dioxy-methyl amphetamine), mescaline, phencyclidine (PCP), donabinol, marijuana/THC, organic solvents, nicotine, Pentobarbital, neuroprotective compounds, neuroprotective peptides, neuroprotective factors, davunetide, antischizophrenic drugs, anti-depression drugs, comtan, Entacopone, anti ADHD agents, and anti ADHD drugs as Methylphenidrate (ritalin), antiautism and anti-autism symptoms drugs, medicaments for treatment of

	Alzheimer's disease, donepezil, galantamine, rivastigmine, Tacrine, insulin, Detemir, Novolin, Humulin, insulin-like hormone, dopamine agonist and dopamine antagonist and any combination thereof ."
17. The composition of claim 16, wherein said empathogen/entactogen is MDMA and is present in a dose of 20-200 mg	 SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8. From page 3 "The choice and dosages of substances used for the sessions MDMA: 80–130 mg
200 mg.	LSD: 50–200µg''
18. The composition of claim 14, wherein said psychedelic is chosen from the group	1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8.
consisting of psilocybin, psilocin, lysergic acid diethylamide (LSD), mescaline	From page 3 "Most psycholytic sessions began with MDMA , then LSD or 2-CB were added mid-way. Sometimes sessions began with 2-CB or with LSD or on rare occasions other substances such as ayahuasca or psilocybin were used."
dimethyltryptamine (DMT), 2,5-dimethoxy- 4-iodoamphetamine (DOI), 2.5-dimethoxy-	17. DMT-NEXUS (2013) "Known substance-interactions and their effects" DMT-Nexus. Retrieved January 25, 2013. https://web.archive.org/web/20130125065447/https://wiki.dmt- nexus.me/Known_substance-interactions_and_their_effects
4-bromoamphetamie (DOB), phenethylamine or tryptamine psychedelics_salts	Max Implicit daminencia meliformations Implicit daminencia Implicit daminencia </td
thereof, analogs thereof, prodrugs thereof, and homologues thereof.	User descriptions: Dante Nice combo. but it wasn't enough to understand its effocts.
	Generic Information: User descriptions: House OK: Profound synetgy: Great for meditation and dance

	Interviewed and provide data data cause mark forcem substance-interactions and their effects Interviewed and the data cause mark forcem substance-interactions and their effects MDAI + DMT Interviewed and the data cause mark forcem substance-interactions and their effects Interviewed and the effect of the DMT seem proformed. MDAI + DMT Interviewed and the effect of the DMT seem proformed. Interviewed and the effect of the DMT seem proformed. User descriptions: Orion Interviewed and the effect of the DMT seem proformed. User descriptions: Orion Interviewed and the effect of the DMT seem proformed. Interviewed and the effect of the DMT seem proformed. Interviewed and the spice effects would last. by up to 25 minutes to grad. User descriptions: Orion Interviewed and the effect of the DMT seem proformed. Interviewed and the effect of the DMT seem proformed. Interviewed and the spice effects would last. by up to 25 minutes to grad. Interviewed and the effect of the DMT seem proformed. Interviewed and the spice of the origin that the spice effects would last. by up to 25 minutes to grad. Interviewed and the effect of the DMT seem proformed. Interviewed and the effect of the spice of the the DMT seem proformed. Interviewed and the effect of the DMT seem proformed and desappear. Interviewed and the spice of the the DMT seem proformed. Interviewed and the effect of the DMT seem proformed
19. The composition of claim 18, wherein said psychedelic is LSD and is present in a dose of 0.05-0.3 mg.	 SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8. From page 3 "The choice and dosages of substances used for the sessions MDMA: 80–130 mg LSD: 50, 200 µg"
20. A method of enhancing positive therapeutic effects of a psychedelic, including the steps of: inducing the release of endogenous monoamines, and stimulating 5- HT.sub.2A receptors.	 LSD: 50–200µg 1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8. From page 3 "MDMA exerts its effects at 5-HT2A and 5-HT2B receptors, creating feelings of reduced anxiety and depression and a sense of euphoria and well-being (Brunner and Hen, 1997; Graeff et al., 1996)." 6. WHITE (1996) "THE EFFECTS OF METHYLENEDIOXYMETHAMPHETAMINE (MDMA, "ECSTASY") ON MONOAMINERGIC NEUROTRANSMISSION IN THE CENTRAL NERVOUS SYSTEM" Progress in Neurobiology. 49, 455-479. From page 456 "It is now well established that administration of single doses of MDMA to laboratory animals induces acute increases in extracellular levels of the monoamines serotonin (5HT), dopamine (DA) and norepinephrine (NE) in several brain regions"
21. The method of claim 20, wherein said inducing step is accomplished by administering an empathogen/entactogen is chosen from the group consisting of 3,4-methylenedioxymetha	 SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary" Drug Science, Policy and Law. 2(0):1-8. From page 3 "MDMA exerts its effects at 5-HT2A and 5-HT2B receptors, creating feelings of reduced anxiety and depression and a sense of euphoria and well-being (Brunner and Hen, 1997; Graeff et al., 1996)."

mphetamine (MDMA),	6. WHITE (1996) "THE EFFECTS OF
3,4-	METHYLENEDIOXYMETHAMPHETAMINE (MDMA, "ECSTASY")
methylendioxyampheta	ON MONOAMINERGIC NEUROTRANSMISSION IN THE CENTRAL
mine (MDA), 3,4,-	NERVOUS SYSTEM" Progress in Neurobiology. 49, 455-479.
methylenedioxyethyla	
mphetamine (MDEA),	From page 456 "It is now well established that administration of single
5,6-methylenedioxy-2-	doses of MDMA to laboratory animals induces acute increases in
aminoindane (MDAI),	extracellular levels of the monoamines serotonin (5HT), dopamine (DA)
mephedrone,	and norepinephrine (NE) in several brain regions"
methylone, 3-MMC,	
homologues thereof,	
analogues thereof, and	
prodrugs thereof.	
22. The method of	1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted
claim 20, wherein said	individual and group psychotherapy in Zurich: Outcomes, implications and
stimulating step is	commentary" Drug Science, Policy and Law. 2(0):1-8.
accomplished by	
administering a	From page 3 "Most psycholytic sessions began with MDMA, then LSD or
psychedelic chosen	2-CB were added mid-way. Sometimes sessions began with 2-CB or with
from the group	LSD or on rare occasions other substances such as ayahuasca or psilocybin
consisting of	were used."
psilocybin, psilocin,	
lysergic acid	17. DMT-NEXUS (2013) "Known substance-interactions and their effects"
diethylamide (LSD),	DMT-Nexus. Retrieved January 25, 2013.
mescaline,	https://web.archive.org/web/20130125065447/https://wiki.dmt-
dimethyltryptamine	nexus.me/Known_substance-interactions_and_their_effects
(DMT), 2,5-dimethoxy-	INTERACT AN CALVER THEPS/Wild.dmt-nexus.me/Known_substance-interactions_and_their_effects
4-iodoamphetamine	25 Jun 2013 - 9 Jun 2021 2013 2014 (* According Spatial)
(DOI), 2,5-dimethoxy-	Mescaline + MDMA
4-bromoamphetamie	Combination: OK
(DOB),	Generic information:
phenethylamine or	Coel descriptions. Demine The Commod data washington inconsistence in static commod and inconsistence in static commod an
tryptamine	
psychedelics, salts	Mushrooms + MDMA
thereof, analogs	Mushrooms + MDMA () Combination: OK
thereof, prodrugs	Generic Information:
thereof, and	User descriptions: House OK. Profound synergy. Great for meditation and dance
homologues thereof.	

	https://www.adelson.identions.adelson.identions.adelson.identions.adelson.identical
	MDAI * DMT
	MDAI + DMT ()
	Combination: OK Generic Information:
	Vaporized hits of DMT seem harder to break through on, but the effect of the DMT seem prolonged. Strange visuals (small
	User descriptions: Orion Opinoin Kaleldoscope patters appear and dissappear; last for longer than the spice effects would last, by up to 25 minutes longer. Does not seem dangerous, but the fact it makes open eye visuals linger for so long is interesting
	TATENET A CATTOR THE PROVIDENT AND A THE AND A
	Ulay Lac (Marching) 20 captures 25 Jan 2017 - 2 Jan 2017
	LSD + MDAI
	LSD + MDAI
	Combination: OK
	User descriptions: The Traveler O The MDAI gives a exphoric effect to the LSD experience.
23. The method of	1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted
claim 20, further	individual and group psychotherapy in Zurich: Outcomes, implications and
including the step of	commentary" Drug Science, Policy and Law. 2(0):1-8.
improving good drug	
effects and reducing	From page 3 "There followed another period of silence followed by music
bad drug effects.	to bring the clients to the point where the MDMA and the LSD or 2-CB met.
5	At the second peak, they would begin the intensive psychotheraneutic
	work again which could last for another five to six hours "
	work again, which could last for another rive to six hours.
	2 LICUT (2012) "Simultaneous nelvauhataneo uso among Danich 2.4
	5. LICHT (2012) Simulateous porysubstance use among Damsin 5,4-
	methylenedioxymethamphetamine and hallucinogen users: combination
	patterns and proposed biological bases" Hum. Psychopharmacol. Clin. Exp.
	27: 352–363.
	From page 355 "The most prevalent observations were cannabis enhancing
	the effects of hallucinogens $(n = 17)$ and MDMA $(n = 7)$, MDMA and
	hallucinogens enhancing each other $(n = 11)$ hallucinogens enhancing
	each other $(n = 6)$ ampletamines $(n = 8)$ and cocaine $(n = 6)$ counteracting
	bally ging gens, and account counterparting the effects of MDMA $(n = 7)$
	handemogens, and cocame counteracting the effects of widwirk (II – /).
	0 DOVG (2001) "IL denote a line margine for denote an entering
	8. BOYS (2001) Understanding reasons for drug use amongst young
	people a functional perspective" Health Education Research. 16(4):457-469.
	From page 465

	Table IV. Combined functional sub	stance use repor	ted by the sample of	over the past y	ear		_
		Cannabis $(n = 153)$	Amphetamines $(n = 60)$	Ecstasy $(n = 43)$	LSD (n = 17)	Cocaine $(n = 44)$	Alcohol $(n = 128)$
	Used with [substance] to improve i	ts effects					
	cannabis	-	16	18	8	14	93
	ecstasy	55	_ 39	20	11	5 19	29 45
	LSD	24	10	9		3	6
	alcohol	42 110	4 38	5 23	1 4	- 29	45
	hallucinogenic mushrooms	2	0	0	1	0	1
		Cannabis $(n = 223)$	Amphetamines $(n = 19)$	Ecstasy $(n = 15)$	LSD (n = 3)	Cocaine $(n = 23)$	Alcohol $(n = 112)$
	Used to help ease after effects of [a cannabis	substance]	5	2	0	4	18
	amphetamines	83	-	6	1	1	47
	ecstasy LSD	114 29	7	-	3	10	59 13
	cocaine	80	1	1	0	-	34
	alcohol	70	18	7	0	14	-
24. The method of	9. HOLZE (2019) "D	Distinct ac	ute effects	of LSD.	MDMA.	and d-	
claim 23 wherein the	amphetamine in healt	thy subject	ets" Neuron	sychoph	armacolo	ogy 45.4	62-471
good drug effects are	umphotamine in neur	ing subject		syenoph	umucon	559. 15. 1	02 171.
good drug effects are	E	N / A	1	£1:	. 6 11 1		
chosen from the group	From page 462 MD	MA acute	ely induces	teelings	of well-I	being, lov	ve,
consisting of drug	empathy, and prosoc	ciality"					
linking, oceanic							
boundlessness,	From page 462 "On	the other	hand, LSD	was four	nd to exh	ibit MDN	/A-like
experience of unity	empathogenic mood	effects su	ch as increa	used clos	eness, or	oenness.	and
spiritual experience	trust"	0110015 54		.5 0 u 0105	eness, o ₁	, penness,	
bligged at a take	ti usi						
blissful state,	E 460						
insightfulness,	From page 468						
connectedness,							
mystical experiences,							
mystical-type effects.							
positive mood							
transcendence of							
time/space, ineffability,							
well-being, trust,							
feelings of love, feeling							
open, peak experience,							
and combinations							
thereof, and the bad							
drug effects are chosen							
from the group							
consisting of anxiety,							
fear, fear of loss of							
body control, anxious-							
ego dissolution,							
disembodiment, fear of							
impaired thought							
control paranoia							
nanic negative							
thoughts grooming							
mougnus, grooming,	1						



 blissful state ("I experienced boundless pleasure"), changed meaning of percepts ("Some everyday things acquired special meaning"), complex imagery ("I saw whole scenes roll by with closed eyes or in complete darkness"), audio-visual synaesthesia ("The colours of things seemed to be altered by sounds or noises"), and elementary imagery ("I saw colours with closed eyes or in complete darkness")." 11. Smigielski (2019) "Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat" Scientific Reports. 9:1-13. From page 2 "Although the content and intensity of psychedelic experiences
depend most critically on dosage, the same dose can induce a pleasurable
state of self-dissolution or, under certain circumstances, a more distressing
response associated with thought disturbances . fear of losing control.
anxiety. or panic."
and of punc.
From page 3 "5D-ASC is designed to quantify positive and negative forms
of self/ego-dissolution including percentual alterations "
or sent ego-unssolution, merduning perceptual anelations.
14 HAI BERSTADT (2018) Rehavioral Neuropiology of Psychodelia
14. HALDERSTADT (2010) Dellavioral Neurobiology of Psychedelic Drugs Springer ISBN: 078-3 662 55878 2
Drugs. Springer 13D14. 770-3-002-33070-2
From nage 227
Primary Dimensions of ASCs – etiology independent - etiology dependent
OBN AED VIR AA VR
Positive derealization + Anxious derealization + Visual elementary and + Anxious derealization + Anxious derealization + Visual elementary and + Anxious derealization + Anxio
Positively experienced Positively experienced Positively experienced Positively experienced Substrain S
+Altered sense of time +Fear of loss of control +Changed meaning of percepts +Hypersensitivity +eight nead mood -overthought +Facilitate drecollection +tailucione +definitione +definitione
ormania-like experience -over body -Facilitated imagination (voices)
Second-order Dimensions
Impaired Control
Experience and Cognition Anxiety of Unity
Elementary
Insightfulness
Spiritual imagery
Experiences
Bliss
Disembodiment changed meaning

21. LIECHII (2017) "Alterations of consciousness and mystical-type
experiences after acute LSD in humans" Psychopharmacology. 234:1499–
1510.
From page 1501 "The 5D-ASC dimension "Oceanic Boundlessness" (27
items) measures derealization and depersonalization associated with positive
emotional states, ranging from heightened mood to euphoric exaltation. The
corresponding lower-order scales include "experience of unity," "spiritual
experience," "blissful state," and "insightfulness." The dimension
"Anxious Ego Dissolution" (21 items) summarizes ego disintegration and
loss of self-control phenomena associated with anxiety. The corresponding
lower-order scales include "disembodiment," "impaired control of
cognition," and "anxiety." The dimension "Visionary Restructuralization"
(18 items) consists of the lower-order scales "complex imagery,"
"elementary imagery," "audio-visual synesthesia," and "changed meaning
of percepts." Two additional dimensions describe "Auditory Alterations"
(15 items) and "Reduction of Vigilance" (12 items) The scale is well-
validated and widely used to characterize the subjective effects of various
valuated and wheely used to characterize the subjective effects of validus
psychedene drugs (Carnan-marris et al. 20100, master et al. 2004, mysek et
al. 2011; Schmid et al. 2015; Vollenweider et al. 2007; Vollenweider and
Kometer 2010)."
From page 1501 "We also derived the four scale scores of the newly
validated revised 30-item MEQ: mystical, positive mood, transcendence of
time and space, and ineffability (Barrett et al. 2015)."
From page 1504

	Table 1 Statistics for the offert-							
	of LSD in the 5D-ASC and MEQ		LSD 10 T test v	Ю µg s. placebo	LSD 200 T test vs	0 µg . placebo	LSD 100 T test	0 vs. 200 μg
			<i>T</i> =	<i>P</i> =	<i>T</i> =	P=	<i>T</i> =	P=
		5 Dimensions Altered States of Con	sciousness	(ASC) scale				
		Total ASC score	9.72	<0.001	10.02	<0.001	2.23	<0.05
		Oceanic boundlessness	8.44	<0.001	9.61	<0.001	1.89	NS
		Anxious ego dissolution	6.43	<0.001	4.01	< 0.001	1.50	NS
		Auditory alterations	3.72	<0.001	5.87	<0.001	0.42	<0.05 NS
		Reductions of vigilance	7.44	<0.001	5.93	<0.001	0.79	NS
		Experience of unity	6.85	<0.001	7.77	<0.001	0.68	NS
		Spiritual experience	4.31	<0.001	3.91	< 0.001	1.10	NS
		Blissful state	6.56	<0.001	8.27	< 0.001	3.00	<0.01
		Disembodiment	4.11 6.93	<0.001	5.81	<0.001	0.13	<0.05 NS
		Impaired control and cognition	7.01	< 0.001	5.04	< 0.001	0.86	NS
		Anxiety	3.02	< 0.001	2.04	NS	1.37	NS
		Complex imagery	7.10	<0.001	7.48	< 0.001	0.31	NS
		Elementary imagery	9.96	<0.001	11.12	< 0.001	0.57	NS
		Changed meaning of percepts	6.25	<0.001	9.66	<0.001	3.39	<0.01
		Ego dissolution (item 71)	7.63	<0.001	5.32	< 0.001	0.36	NS
		Mystical Effects Questionnaire (ME	C43)					
		Internal unity	NA	NA	6.22	< 0.001	NA	NA
		External unity	NA	NA	6.08	< 0.001	NA	NA
		Noetic quality	NA	NA	6.80 5.71	<0.001	NA	NA
		Deeply felt positive mood	NA	NA	11.43	<0.001	NA	NA
		Transcendence of time/space	NA	NA	10.63	< 0.001	NA	NA
		Ineffability	NA	NA	16.22	< 0.001	NA	NA
		Mystical Effects Questionnaire (ME	Q30)					
		Mystical	NA	NA	5.99	<0.001	NA	NA
		Transcendence of time/space	NA	NA	13.13	<0.001	NA	NA
		Ineffability	NA	NA	25.14	< 0.001	NA	NA
		MEC30 total score	NA	NA	14.91	< 0.001	NA	NA
25. A method of treating a patient including the step of:	1. SESSA (2015) individual and gro commentary" Dru	"Underground Ml oup psychotherapy 1g Science, Policy	DMA v in Z and 1	-, LSE Jurich: Law. 2)- and Outco (0):1-	l 2-CB omes, -8.	-assis impli	sted cations a
enhancing a mood of					(-)-			
psychedelic treatment	From page 3 "Me 2-CB were added LSD or on rare of were used."	ost psycholytic ses d mid-way . Somet ccasions other subs	sions times stanc	begar sessio es such	n with ms be n as ay	n MDN gan w yahuas	MA, t ith 2- sca or	hen LSI CB or w psilocyl
26. The method of claim 25, wherein said enhancing step is further defined as administering an empathogen/entectogen	From page 3 "Me 2-CB were added LSD or on rare of were used." 1. SESSA (2015) individual and gro commentary" Dro From page 3 "Me 2-CB were added	ost psycholytic ses d mid-way. Somet ccasions other subs "Underground MI oup psychotherapy ug Science, Policy ost psycholytic ses d mid-way. Somet	sions times stance DMA v in Z and 1 sions	begar sessio es such -, LSE furich: Law. 2 begar	- and O- and Outco (0):1-	n MDN gan w yahuas 1 2-CB omes, -8.	MA, t ith 2- sca or B-assis implie MA, t	hen LSI CB or w psilocyl sted cations a hen LSI

mine (MDA), 3,4,-16. CHARY (2018) "Candyflipping and Other Combinations: Identifying methylenedioxyethyla Drug-Drug Combinations from an Online Forum" Frontiers Psychiatry. 9:1mphetamine (MDEA), 9. 5,6-methylenedioxy-2aminoindane (MDAI), From page 5 "In the synthetic hallucinogen, LSD is a hub that bridges two mephedrone, subislands. The left subisland of the hallucinogen island contains substances methylone, 3-MMC, canonically thought to be anticholinergic. Hyoscine and hyoscyamine are homologues thereof, tropane alkaloids found in jimson weed. The right subisland contains analogues thereof, and amphetamine derivatives, such as MDMA and the MDMA derivatives prodrugs thereof. (bath salts), bk-MDMA (β-keto MDMA; methylone) and bk-MDEA (ethylone)." 17. DMT-NEXUS (2013) "Known substance-interactions and their effects" DMT-Nexus. Retrieved January 25, 2013. https://web.archive.org/web/20130125065447/https://wiki.dmtnexus.me/Known substance-interactions and their effects WayBackMachine Mescaline + MDMA https://wiki. ۲ Wallack Achine 20 c MDAI + DMT 20 captures LSD + MDAI **27.** The method of 1. SESSA (2015) "Underground MDMA-, LSD- and 2-CB-assisted claim 25, wherein the individual and group psychotherapy in Zurich: Outcomes, implications and psychedelic is chosen commentary" Drug Science, Policy and Law. 2(0):1-8. from the group consisting of From page 3 "Most psycholytic sessions began with MDMA, then LSD or psilocybin, psilocin, 2-CB were added mid-way. Sometimes sessions began with 2-CB or with lysergic acid



insightfulness,	Table IV. Combined functional substance use reported by the sample over the past year						
mystical-type		Cannabis	Amphetamines	Ecstasy	LSD	Cocaine	Alcohol
experience, and		(n = 153)	(n = 60)	(n = 43)	(n = 17)	(n = 44)	(n = 128)
positively experienced	Used with [substance] to improve its effects						
nsychedelic effects	amphetamines	37	16 -	18 20	8 7	14 3	93 29
psychedene effects,	ecstasy	55	39	-	11	19	45
aspects of ego-	LSD	24 42	10	9 5	-	3	6 45
dissolution, and	alcohol	110	38	23	4	29	-
combinations thereof,	hallucinogenic mushrooms	2	0	0	1	0	1
and decreasing negative		Cannabis $(n = 223)$	Amphetamines $(n = 19)$	Ecstasy $(n = 15)$	LSD $(n = 3)$	Cocaine $(n = 23)$	Alcohol $(n = 112)$
acute effects chosen		(n - 223)	(n - 19)	(n - 15)	(n - 3)	(n - 23)	(n - 112)
from the group	Used to help ease after effects of [s cannabis	substance]	5	2	0	4	18
consisting of bad drug	amphetamines	83	_	6	1	1	47
	ecstasy LSD	114 29	7	5	3	10	59 13
effect, anxiety, fear,	cocaine	80	1	1	0	-	34
increased ratings of	alcohol	70	18	7	0	14	-
anxious ego-							
dissolution.	0 1101 7E (2010) "F	Nictinat as	uta affaata (ficn		andd	
descriptions of acute	9. HOLZE (2019) L		ute effects (JI LSD,	MDMA,	and d-	(0. 1=1
normania states of	amphetamine in heal	thy subject	ets" Neurop	sychoph	armacolo	ogy. 45:40	62-471.
paranola, states of							
panic and anxiety, and	From page 462 "MD	MA prod	uced greate	r ratings	of good	drug eff	ects,
combinations thereof.	liking high and ego	dissolutio	on compare	d with d	.amnheta	mine d-	,
	inking , ingit, and ego dissolution compared with d-amphetamine. d-						
	Amphetamine increased ratings of activity and concentration compared with						
	LSD."						
	From page 462 "MD	MA acute	elv induces	feelings	of well-t	oeing, lov	ve.
	emnathy and prosoc	viality"	<i>.</i>	0		8)	-)
	cinpatity, and prosoc	Juilty					
	Erom nago 162 "On	the other	hand ICD	waa faar	d to orb	: 	(A like
	FIOID page 402 OI			was iour	id to exil		A-like
	empathogenic mood	effects su	ch as increa	ised clos	eness, op	oenness,	and
	trust"						
	From page 468						



• blissful state ("I experienced boundless pleasure"),
 changed meaning of percepts ("Some everyday things acquired
special meaning"),
• complex imagery ("I saw whole scenes roll by with closed eyes or
in complete darkness"),
• audio-visual synaesthesia ("The colours of things seemed to be
altered by sounds or noises"), and
 elementary imagery ("I saw colours with closed eyes or in complete darkness")."
11. Smiglelski (2019) "Characterization and prediction of acute and
Scientific Reports 0:1.13
Scientific Reports. 9.1-15.
From page 2 "Although the content and intensity of psychedelic experiences depend most critically on dosage, the same dose can induce a pleasurable state of self-dissolution or, under certain circumstances, a more distressing response associated with thought disturbances , fear of losing control, anxiety, or panic."
From page 3 "5D-ASC is designed to quantify positive and negative forms
of self/ego-dissolution, including perceptual alterations."
14. HALBERSTADT (2018) Behavioral Neurobiology of Psychedelic
Drugs. Springer ISBN: 978-3-662-55878-2
From page 227



21. LIECHTI (2017) "Alterations of consciousness and mystical-type experiences after acute LSD in humans" Psychopharmacology. 234:1499–1510.

From page 1501 "The 5D-ASC dimension "Oceanic Boundlessness" (27 items) measures derealization and depersonalization associated with positive emotional states, ranging from heightened mood to euphoric exaltation. The corresponding lower-order scales include "experience of unity," "spiritual experience," "blissful state," and "insightfulness." The dimension "Anxious Ego Dissolution" (21 items) summarizes ego disintegration and loss of self-control phenomena associated with anxiety. The corresponding lower-order scales include "disembodiment," "impaired control of cognition," and "anxiety." The dimension "Visionary Restructuralization" (18 items) consists of the lower-order scales "complex imagery," "elementary imagery," "audio-visual synesthesia," and "changed meaning of percepts." Two additional dimensions describe "Auditory Alterations" (15 items) and "Reduction of Vigilance" (12 items). The scale is wellvalidated and widely used to characterize the subjective effects of various psychedelic drugs (Carhart-Harris et al. 2016b; Hasler et al. 2004; Hysek et al. 2011; Schmid et al. 2015; Vollenweider et al. 2007; Vollenweider and Kometer 2010)."

From **page 1501** "We also derived the four scale scores of the newly validated revised 30-item MEQ: **mystical**, positive mood, **transcendence of time and space**, and **ineffability** (Barrett et al. 2015)."

From page 1504

of LSD in the 5D-ASC and MEQ	LSD 10 T test v	LSD 100 µg T test vs. placebo		LSD 200 µg T test vs. placebo		LSD 100 vs. 200 µg T test	
	<i>T</i> =	<i>P</i> =	<i>T</i> =	P=	<i>T</i> =	P=	
5 Dimensions Altered States of	Consciousness	(ASC) scale					
Total ASC score	9.72	< 0.001	10.02	< 0.001	2.23	< 0.05	
Oceanic boundlessness	8.44	< 0.001	9.61	< 0.001	1.89	NS	
Anxious ego dissolution	6.43	< 0.001	4.01	< 0.001	1.50	NS	
Visionary restructuralization	9.79	< 0.001	15.32	< 0.001	2.34	< 0.05	
Auditory alterations	3.72	< 0.01	5.87	< 0.001	0.42	NS	
Reductions of vigilance	7.44	< 0.001	5.93	< 0.001	0.79	NS	
Experience of unity	6.85	< 0.001	7.77	< 0.001	0.68	NS	
Spiritual experience	4.31	< 0.001	3.91	< 0.001	1.10	NS	
Blissful state	6.56	< 0.001	8.27	< 0.001	3.00	< 0.01	
Insightfulness	4.11	< 0.001	5.81	< 0.001	2.28	< 0.05	
Disembodiment	6.93	< 0.001	5.87	< 0.001	0.13	NS	
Impaired control and cognitio	n 7.01	< 0.001	5.04	< 0.001	0.86	NS	
Anxiety	3.02	< 0.001	2.04	NS	1.37	NS	
Complex imagery	7.10	< 0.001	7.48	< 0.001	0.31	NS	
Elementary imagery	9.96	< 0.001	11.12	< 0.001	0.57	NS	
Audio-visual synsthesia	9.19	< 0.001	12.52	< 0.001	1.96	NS	
Changed meaning of percepts	6.25	< 0.001	9.66	< 0.001	3.39	< 0.01	
Ego dissolution (item 71)	7.63	<0.001	5.32	< 0.001	0.36	NS	
Mystical Effects Questionnaire (MEC43)						
Internal unity	NA	NA	6.22	< 0.001	NA	NA	
External unity	NA	NA	6.08	< 0.001	NA	NA	
Sacredness	NA	NA	6.80	< 0.001	NA	NA	
Noetic quality	NA	NA	5.71	< 0.001	NA	NA	
Deeply felt positive mood	NA	NA	11.43	< 0.001	NA	NA	
Transcendence of time/space	NA	NA	10.63	< 0.001	NA	NA	
Ineffability	NA	NA	16.22	< 0.001	NA	NA	
Mystical Effects Questionnaire (MEQ30)						
Mystical	NA	NA	5.99	< 0.001	NA	NA	
Positive mood	NA	NA	13.13	< 0.001	NA	NA	
Transcendence of time/space	NA	NA	11.12	< 0.001	NA	NA	
Ineffability	NA	NA	25.14	< 0.001	NA	NA	
	NA	NA	14.91	< 0.001	NA	NA	

Electronic Acknowledgement Receipt					
EFS ID:	45481254				
Application Number:	17238088				
International Application Number:					
Confirmation Number:	8795				
Title of Invention:	MDMA TREATMENT TO ENHANCE ACUTE EMOTIONAL EFFECTS PROFILE OF LSD, PSILOCYBIN, OR OTHER PSYCHEDELICS				
First Named Inventor/Applicant Name:	Matthias Emanuel LIECHTI				
Customer Number:	48924				
Filer:	Shahin Shams				
Filer Authorized By:					
Attorney Docket Number:	0614.00040				
Receipt Date:	14-APR-2022				
Filing Date:	22-APR-2021				
Time Stamp:	22:49:42				
Application Type:					

Payment information:

Submitted with Payment	yes			
Payment Type	CARD			
Payment was successfully received in RAM	\$90			
RAM confirmation Number	E20224DM49382561			
Deposit Account				
Authorized User				
The Divertey of the UCDTO is hereby owthey include a charge indicated face and available over a verse we are the follower				

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
			393893		36
1	Concise Description of Relevance	ClaimsChartFinal.pdf	64409779cd90746e9cf186fafc6c93fcca219 a96	no	
Warnings:		•	•		
Information:					
			836250	no	12
2	Evidence of Publication	21-LIECHTI.pdf	95e01161bae250968188ae2cca20795c77b 26a56		
Warnings:		1	•		
Information:					
			32677		2
3	Concise Description of Relevance	Concise-description-generated. pdf	928611ed02d40fdef555baefda628d989c56 bbb7	no	
Warnings:		ł			
Information:					
			52935		2
4	Third-Party Submission Under 37 CFR 1.290	Third-party-preissuance- submission.pdf	f448e7581775ab037c514460a2f4e565a197 2cc8	no	
Warnings:		l	•		
Information:					
		Third-party-notification- request.pdf	23722		1
5	Request for Notification of Non- compliant Third-Party Submission		c7d779a56dcc794b3f5d5f44cc3fffcce059c b2c	no	
Warnings:		ł	1		
Information:					
			37413		
6	6 Fee Worksheet (SB06) fee-i		fef4705f40f348ae80566f07326b92bd3dbb a9b5	no	2
Warnings:		·	·		
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.